Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.